

This document is a translation of the original Japanese document for reference purposes only. In the event of any discrepancy between this document and the Japanese original, the original shall prevail.



February 13, 2026

Company name: MatsukiyoCocokara & Co.
Listing: Prime Market, Tokyo Stock Exchange
Stock code: 3088
Representative: Kiyoo Matsumoto,
President and Representative Director
Contact: Akio Ishibashi,
Managing Director,
Head of Group Management Planning
TEL: +81-3-6672-7808

**Notice Concerning Acquisition of Shares of UNIVERSAL DRUG CO.,LTD.
by a Subsidiary of MatsukiyoCocokara & Co.**

MatsukiyoCocokara & Co. hereby announces that at the Board of Directors meeting held on February 13, 2026, we resolved that our subsidiary, And Company Co.,Ltd. (hereinafter "And Company") will acquire shares of UNIVERSAL DRUG CO.,LTD. (hereinafter " UNIVERSAL DRUG") and make it a subsidiary.

1. Reason for share acquisition

We based on our group vision "Making health and beauty more delightful and accessible", we actively incorporate new technologies and ideas mainly in the fields of health and beauty, aiming to make people's daily lives more fun and enjoyable. We continue to strive in its efforts to remain close and sensitive to the wishes and desires of consumers, and strive to deliver greater peace of mind and joy to the daily lives of people and their communities. In addition, we aim to expand our core business of Drugstore business and Dispensing pharmacy business, as well as realize our vision of an alliance in which like-minded colleagues (companies) gather to achieve future growth together. UNIVERSAL DRUG operates 20 drugstore and dispensing pharmacies in the Tokyo Metropolitan and Saitama Prefectures. Under the theme of "Health and Beauty," the stores aim to be "Medical institutions where customers can consult with their nearest and dearest" for local customers and patients by providing advice for clean and comfortable life and promoting self-medication.

In order to realize the alliance concept and further expand the scale of business, which were set as medium-term management targets for the fiscal year ending March 31, 2031, And Company has decided to acquire 100% of the shares of UNIVERSAL DRUG and invite it into the Group.

2. Overview of the transferred subsidiary (UNIVERSAL DRUG CO.,LTD.)

(1)	Company name	UNIVERSAL DRUG CO.,LTD.
(2)	Head office	1-3-1 Nakazato, Kita-ku, Tokyo
(3)	Title and name of the representative	Hajime Shinoda President Representative Director
(4)	Business description	Drugstore business, Dispensing pharmacy business
(5)	Share capital	10 million yen

(6)	Established	June 3, 1986	
(7)	Latest net sales	4,575 million yen (Fiscal year ended August 31, 2025)	
(8)	Major shareholders and percentage of shares	We refrain from disclosing this information because the major shareholder is an individual and we have entered into a confidentiality agreement.	
(9)	Relationship with the company	capital ties	No items to be reported
		human relationship	same as above
		business relationship	same as above

3. Number of shares to be acquired, acquisition price, and shareholding before and after the acquisition

(1)	Number of shares held before the transfer	0 shares (Number of voting rights: 0) (Percentage of voting rights: 0.0%)
(2)	Number of shares bought back	200 shares (Number of voting rights: 200) (Percentage of voting rights: 100.0%)
(3)	Cost	The acquisition price is determined in consultation with the counterparty based on the results of the shareholder value calculation by a third party organization, but we refrain from disclosing it due to the conclusion of a confidentiality agreement.
(4)	Shares owned after the transaction	200 shares (Number of voting rights: 200) (Percentage of voting rights: 100.0%)

4. Outline of the subsidiary acquiring the shares

(1)	Company Name	And Company Co.,Ltd.
(2)	Head office	MK Ochanomizu Building, 7F, 1-8-2 Yushima, Bunkyo-ku, Tokyo
(3)	Title and name of the representative	Kiyoo Matsumoto President of Representative Director
(4)	Business description	Management and supervision of Group companies such as Drugstores
(5)	Share capital	50 million yen
(6)	Established	August 1, 2025
(7)	Major shareholders and percentage of shares	MatsukiyoCocokara & Co. (100.0%)

5. Schedule

(1)	The date of resolution, Board of Directors	February 13, 2026
(2)	date of signing contract	February 13, 2026
(3)	Date of share transfer	April 1, 2026 (scheduled)

6. Future Outlook

As the Company plans to acquire the shares on April 1, 2026, the Company recognizes that the impact of this matter on its business performance for the fiscal year ending March 31, 2026 will be minimal. However, the Company will promptly announce any matters that require disclosure if they arise.

(Reference) Management Organizational Structure

